HERON THERAPEUTICS ($HRTX) posted quarterly earnings results on Tuesday, May 6th. The company reported earnings of $0.01 per share, beating estimates of -$0.01 by $0.02. The company also reported revenue of $38,900,000, beating estimates of $38,165,003 by $734,997.
You can see Quiver Quantitative's $HRTX stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
HERON THERAPEUTICS Hedge Fund Activity
We have seen 63 institutional investors add shares of HERON THERAPEUTICS stock to their portfolio, and 86 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- POINT72 ASSET MANAGEMENT, L.P. added 3,075,809 shares (+inf%) to their portfolio in Q4 2024, for an estimated $4,705,987
- CITADEL ADVISORS LLC removed 1,591,547 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $2,435,066
- PALISADE CAPITAL MANAGEMENT, LP added 1,360,542 shares (+34.7%) to their portfolio in Q1 2025, for an estimated $2,993,192
- QUBE RESEARCH & TECHNOLOGIES LTD removed 1,146,658 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $1,754,386
- GOLDMAN SACHS GROUP INC removed 1,051,992 shares (-61.6%) from their portfolio in Q4 2024, for an estimated $1,609,547
- MORGAN STANLEY added 1,025,837 shares (+58.0%) to their portfolio in Q4 2024, for an estimated $1,569,530
- RENAISSANCE TECHNOLOGIES LLC removed 819,398 shares (-40.8%) from their portfolio in Q4 2024, for an estimated $1,253,678
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
